{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:34:55Z","timestamp":1783114495847,"version":"3.54.6"},"reference-count":129,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 CA090628"],"award-info":[{"award-number":["K12 CA090628"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jtho.2019.06.020","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T12:18:27Z","timestamp":1561724307000},"page":"1704-1717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pathologic Considerations and Standardization in Mesothelioma Clinical Trials"],"prefix":"10.1016","volume":"14","author":[{"given":"Ming-Sound","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre L.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja C.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hesdorffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Taioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.06.020_bib1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2019.06.020_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtho.2019.06.020_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A\u00a0systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib7","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.06.020_bib10","author":"Hassan"},{"key":"10.1016\/j.jtho.2019.06.020_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib16","author":"Okada"},{"key":"10.1016\/j.jtho.2019.06.020_bib17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2019.06.020_bib21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti\u2013PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2017.01.004","article-title":"Immune checkpoint inhibition in malignant mesothelioma: does it have a future?","volume":"105","author":"Mansfield","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-642-10862-4_4","article-title":"Biopsy techniques for the diagnosis of mesothelioma","volume":"189","author":"Walters","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib24","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.06.020_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5","article-title":"Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging","volume":"72","author":"Boutin","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib26","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1378\/chest.09-0884","article-title":"Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial","volume":"137","author":"Metintas","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2019.06.020_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1148\/radiol.2412051020","article-title":"Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy","volume":"241","author":"Agarwal","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2019.06.020_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1440-1843.2011.01973.x","article-title":"Pleural controversy: close needle pleural biopsy or thoracoscopy-which first?","volume":"16","author":"Koegelenberg","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.jtho.2019.06.020_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2019.06.020_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000474952","article-title":"Frozen sections in pleural pathology: a valuable tool","volume":"94","author":"Karpathiou","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.jtho.2019.06.020_bib31","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2019.06.020_bib32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/JTO.0b013e31820ce2c7","article-title":"Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma","volume":"6","author":"Kao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.5858\/arpa.2016-0073-OA","article-title":"Dataset for reporting of malignant mesothelioma of the pleura or peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib34","unstructured":"Dacic S BK, Baker TP, Beasley MB, et\u00a0al. Protocol for the examination of specimens from patients with malignant pleural mesothelioma. 2017:1-9."},{"key":"10.1016\/j.jtho.2019.06.020_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/PAP.0000000000000180","article-title":"Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples","volume":"25","author":"Monaco","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/dc.23683","article-title":"Utility of BRCA1-associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens","volume":"45","author":"McCroskey","year":"2017","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib38","author":"Roy-Chowdhuri"},{"key":"10.1016\/j.jtho.2019.06.020_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cncy.21660","article-title":"Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens","volume":"124","author":"Sauter","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib40","series-title":"IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer","author":"Tsao","year":"2017"},{"key":"10.1016\/j.jtho.2019.06.020_bib41","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer","volume":"35","author":"Buttner","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s11948-013-9503-y","article-title":"\u201cMirroring\u201d the ethics of biobanking: what should we learn from the analysis of consent documents[corrected]?","volume":"20","author":"Serepkaite","year":"2014","journal-title":"Sci Eng Ethics"},{"key":"10.1016\/j.jtho.2019.06.020_bib43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12910-017-0232-7","article-title":"Participatory improvement of a template for informed consent documents in biobank research \u2014 study results and methodological reflections","volume":"18","author":"Bossert","year":"2017","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.jtho.2019.06.020_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/medethics-2017-104241","article-title":"Ethics of dead participants: policy recommendations for biobank research","volume":"44","author":"Ursin","year":"2018","journal-title":"J\u00a0Med Ethics"},{"key":"10.1016\/j.jtho.2019.06.020_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145100","article-title":"The Influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) biobank","volume":"11","author":"Guerrera","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2019.06.020_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/bio.2015.0009","article-title":"Impact of in\u00a0vivo ischemic time on RNA quality\u2014experiences from a colon cancer biobank","volume":"13","author":"Olsen","year":"2015","journal-title":"Biopreserv Biobank"},{"key":"10.1016\/j.jtho.2019.06.020_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clinbiochem.2014.01.002","article-title":"The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings","volume":"47","author":"Shabihkhani","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jtho.2019.06.020_bib48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/bio.2017.0104","article-title":"Quality assurance after a natural disaster: lessons from hurricane sandy","volume":"16","author":"Dickerson","year":"2018","journal-title":"Biopreserv Biobank"},{"key":"10.1016\/j.jtho.2019.06.020_bib49","first-page":"JOP1800092","article-title":"What can be done to improve research biopsy quality in oncology clinical trials?","author":"Ferry-Galow","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtho.2019.06.020_bib50","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.27916","article-title":"Feasibility and safety of sequential research-related tumor core biopsies in clinical trials","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2013.12.003","article-title":"Collection, integration and analysis of cancer genomic profiles: from data to insight","volume":"24","author":"Gao","year":"2014","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.jtho.2019.06.020_bib52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1471-2407-8-236","article-title":"National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research","volume":"8","author":"Amin","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib53","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart","volume":"10","author":"Travis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2019.06.020_bib55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2019.06.020_bib56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.12.006","article-title":"Improving the accuracy of mesothelioma diagnosis in China","volume":"12","author":"Guo","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib58","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamaoncol.2016.5487","article-title":"Association of asbestos exposure with malignant mesothelioma incidence in Eastern China","volume":"3","author":"Mao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib59","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00000478-199405000-00002","article-title":"Deciduoid peritoneal mesothelioma. An unusual phenotype affecting young females","volume":"18","author":"Nascimento","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in Malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41379-018-0127-2","article-title":"Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42","volume":"32","author":"Stevers","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib64","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1148\/rg.336135512","article-title":"Primary pericardial tumors","volume":"33","author":"Restrepo","year":"2013","journal-title":"Radiographics"},{"key":"10.1016\/j.jtho.2019.06.020_bib65","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2169\/internalmedicine.0355-17","article-title":"The antemortem diagnosis of primary malignant pericardial mesothelioma: a multidisciplinary evaluation","volume":"57","author":"Shikano","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib66","doi-asserted-by":"crossref","first-page":"4810901","DOI":"10.1155\/2016\/4810901","article-title":"Pericardial effusion due to primary malignant pericardial mesothelioma: a common finding but an uncommon cause","volume":"2016","author":"Istomin","year":"2016","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.carpath.2009.08.003","article-title":"Post-irradiation pericardial malignant mesothelioma: an autopsy case and review of the literature","volume":"19","author":"Bendek","year":"2010","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5858\/arpa.2010-0550-RS","article-title":"Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis","volume":"136","author":"Chekol","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/PAS.0b013e31829ab20e","article-title":"Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases","volume":"38","author":"Lee","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2012.05.014","article-title":"Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update","volume":"44","author":"Ordonez","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/modpathol.2011.173","article-title":"p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma","volume":"25","author":"Bishop","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib72","doi-asserted-by":"crossref","first-page":"59314","DOI":"10.18632\/oncotarget.10653","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non\u2013small cell lung carcinomas from malignant mesothelioma","volume":"7","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2019.06.020_bib73","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2019.06.020_bib74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non\u2013small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib76","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2019.06.020_bib77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2018.05.012","article-title":"The diagnostic role of BAP1 in serous effusions","volume":"79","author":"Davidson","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib79","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 Project","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib81","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2019.06.020_bib83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JTO.0000000000000466","article-title":"Recent insights emerging from malignant mesothelioma genome sequencing","volume":"10","author":"Carbone","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib84","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2019.06.020_bib85","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2019.06.020_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib87","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib88","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2019.06.020_bib89","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.mayocp.2018.01.032","article-title":"Effects of reduction in tumor burden on survival in epithelioid malignant pleural mesothelioma","volume":"93","author":"Mansfield","year":"2018","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.jtho.2019.06.020_bib90","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib91","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1309\/AJCPOATJ9L4GCGDA","article-title":"p16\/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer","volume":"143","author":"Ito","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2019.06.020_bib92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2016.07.011","article-title":"Low homozygous\/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma","volume":"99","author":"Hamasaki","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib93","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.21037\/jtd.2018.03.33","article-title":"Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma","volume":"10","author":"Hung","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2019.06.020_bib94","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \u201ccancer immunogram.\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2019.06.020_bib95","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib96","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1\u2013ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2019.06.020_bib97","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1158\/1078-0432.CCR-15-2246","article-title":"Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer","volume":"22","author":"Mansfield","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib98","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A\u00a0proposal for validation of antibodies","volume":"13","author":"Uhlen","year":"2016","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtho.2019.06.020_bib99","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A\u00a0prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib100","doi-asserted-by":"crossref","first-page":"11982","DOI":"10.1073\/pnas.1300136110","article-title":"Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue","volume":"110","author":"Gerdes","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2019.06.020_bib101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtho.2019.06.020_bib102","doi-asserted-by":"crossref","first-page":"301ra131","DOI":"10.1126\/scitranslmed.aac5624","article-title":"High-throughput pairing of T cell receptor alpha and beta sequences","volume":"7","author":"Howie","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-016-0335-7","article-title":"Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq","volume":"8","author":"Redmond","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1026504","article-title":"Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma","volume":"4","author":"Grotz","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2019.06.020_bib105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2019.06.020_bib106","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib107","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2019.06.020_bib108","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non\u2013small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib109","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2019.06.020_bib110","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41598-018-20622-8","article-title":"Contraction of T cell richness in lung cancer brain metastases","volume":"8","author":"Mansfield","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2019.06.020_bib111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3800","article-title":"The problem with neoantigen prediction","volume":"35","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtho.2019.06.020_bib112","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2019.06.020_bib113","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tcb.2012.04.006","article-title":"The Hippo signaling pathway and stem cell biology","volume":"22","author":"Ramos","year":"2012","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jtho.2019.06.020_bib114","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41416-019-0379-8","article-title":"MST1\/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial","volume":"120","author":"Maille","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib116","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/jcmm.13593","article-title":"Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma","volume":"22","author":"Hsu","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"Reporting recommendations for tumour marker prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib118","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ejca.2005.03.032","article-title":"Reporting recommendations for tumour marker prognostic studies (REMARK)","volume":"41","author":"McShane","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib119","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2019.06.020_bib121","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ncponc0252","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"2","author":"McShane","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib122","first-page":"99","article-title":"Reporting recommendations for tumor marker prognostic studies (remark)","volume":"28","author":"McShane","year":"2006","journal-title":"Exp Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib123","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A\u00a0systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","article-title":"Progress and challenges in Mesothelioma: from bench to bedside","volume":"134","author":"Blyth","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jtho.2019.06.020_bib125","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib127","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.trecan.2016.07.004","article-title":"Malignant mesothelioma: time to translate?","volume":"2","author":"Napolitano","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtho.2019.06.020_bib128","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"State of the art: concise review scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.020_bib129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/thoraxjnl-2014-206464","article-title":"Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies","volume":"70","author":"Blyth","year":"2015","journal-title":"Thorax"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419305027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419305027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:12Z","timestamp":1761561612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419305027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":129,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1556086419305027"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.06.020","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic Considerations and Standardization in Mesothelioma Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}